首页> 外文期刊>The journal of clinical psychiatry >Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine.
【24h】

Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine.

机译:血清脑衍生的神经营养因子水平之间缺乏关联,在一双盲,随机,安慰剂对照试验中缺乏精神分裂症症状,作为氯氮平的辅助治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

To the Editor: We have shown that memantine as adjunctive therapy to clozapine improves negative and positive symptoms in patients with refractory schizophrenia.1 However, the biologic mechanism for this improvement remains unclear. Meisner et al2 have reported an interaction between memantine and brain-derived neurotrophic factor (BDNF). An effect of memantine on nonneuronal BDNF-producing cells may explain this interaction by activation of extrasynaptic N-methyl-D-aspartate receptors and promotion of neuronal functioning. BDNF is implicated in many psychiatric disorders, such as schizophrenia.
机译:对于编辑:我们已经表明,Memantine作为氯氮平的辅助治疗改善了难治性精神分裂症患者的阴性和阳性症状.1然而,这种改进的生物机制仍不清楚。 Meisner等Al2报道了Memantine和脑衍生的神经营养因子(BDNF)之间的相互作用。 Memantine对非生物细胞产生的影响可以通过激活额外的N-甲基-D-天冬氨酸受体和神经元功能的促进来解释这种相互作用。 BDNF涉及许多精神病疾病,例如精神分裂症。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号